{"id":17457,"date":"2018-03-12T11:44:36","date_gmt":"2018-03-12T10:44:36","guid":{"rendered":"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/"},"modified":"2018-03-12T12:15:33","modified_gmt":"2018-03-12T11:15:33","slug":"la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores","status":"publish","type":"post","link":"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/","title":{"rendered":"La Comisi\u00f3n Europea publica la opini\u00f3n de sus expertos sobre modelos de financiaci\u00f3n de medicamentos innovadores"},"content":{"rendered":"

Antecedentes<\/strong><\/p>\n

El \u201cExpert Panel on effective ways of investing in Health\u201d se constituy\u00f3 con el objetivo de proporcionar asesoramiento no vinculante a la Comisi\u00f3n sobre cuestiones relacionadas con la eficacia, el acceso y la resiliencia de los sistemas de salud.<\/p>\n

El dictamen que comentamos, titulado \u201cInnovative payment models for high-cost innovative medicines\u201d, es interesante ya que ofrece una visi\u00f3n general de algunos principios b\u00e1sicos de los nuevos modelos de financiaci\u00f3n de los medicamentos innovadores.<\/p>\n

Opini\u00f3n de los expertos<\/p>\n

Los principios b\u00e1sicos que seg\u00fan el panel de expertos deber\u00edan imperar en los nuevos modelos de financiaci\u00f3n son los siguientes:<\/p>\n

– Se recomienda que las compa\u00f1\u00edas farmac\u00e9uticas presenten a las autoridades una estimaci\u00f3n de los costes en los que hayan incurrido en investigaci\u00f3n, en aras de una mayor transparencia.<\/p>\n

– Se anima a los sistemas de salud a explorar formas de fomentar la innovaci\u00f3n distintas al sistema de patentes y prever que el sector p\u00fablico participe en los retornos del I+D que financia.<\/p>\n

– Se determina que no hay un modelo \u00fanico para medir el valor y los resultados de los medicamentos innovadores, pero que es esencial incrementar la comparabilidad de los datos, preferiblemente entre varios pa\u00edses, as\u00ed como mejorar la retribuci\u00f3n para el valor terap\u00e9utico a\u00f1adido.<\/p>\n

– Se apoya la idea de introducir en la negociaci\u00f3n de precio mecanismos para controlar, a trav\u00e9s de las autoridades de competencia, las situaciones de abuso de poder de mercado.<\/p>\n

– Se considera que no existe un modelo que sirva para todos los escenarios, sino que varios modelos deben coexistir y ser usados en funci\u00f3n de cada caso.<\/p>\n

– Se apunta a la compra de soluciones integrales en salud, de servicios, como una alternativa a la compra simplemente de productos, y se considera que avanzar en esta direcci\u00f3n permitir\u00e1 retribuir mejor los tratamientos efectivos.<\/p>\n

– Asimismo, se aboga por crear plataformas de di\u00e1logo que impliquen a autoridades y a representantes de compa\u00f1\u00edas farmac\u00e9uticas.<\/p>\n

El dictamen del panel de expertos es una herramienta de alto valor en el contexto actual, y sintetiza ideas de notable inter\u00e9s. Tal vez se echa en falta una apuesta m\u00e1s clara por la incorporaci\u00f3n de las posibilidades infinitas del \u201cReal World Evidence\u201d\u00a0a los mecanismos de medici\u00f3n de resultados en salud. El Big Data, con seguridad, jugar\u00e1 un papel fundamental en las decisiones de precio y reembolso de medicamentos y de otras intervenciones sanitarias en un futuro no muy lejano.<\/p>\n","protected":false},"excerpt":{"rendered":"

Antecedentes El \u201cExpert Panel on effective ways of investing in Health\u201d se constituy\u00f3 con el objetivo de proporcionar asesoramiento no vinculante a la Comisi\u00f3n sobre cuestiones relacionadas con la eficacia, el acceso y la resiliencia de los sistemas de salud. El dictamen que comentamos, titulado \u201cInnovative payment models for high-cost innovative medicines\u201d, es interesante ya… <\/p>\n

<\/div>\n

M\u00e9s informaci\u00f3<\/a><\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[272,286,309],"tags":[],"coauthors":[],"class_list":["post-17457","post","type-post","status-publish","format-standard","hentry","category-capsulas-ca","category-dret-farmaceutic-i-life-sciences","category-preu-i-financament-public"],"acf":[],"yoast_head":"\nLa Comisi\u00f3n Europea publica la opini\u00f3n de sus expertos sobre modelos de financiaci\u00f3n de medicamentos innovadores - Faus Moliner<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La Comisi\u00f3n Europea publica la opini\u00f3n de sus expertos sobre modelos de financiaci\u00f3n de medicamentos innovadores - Faus Moliner\" \/>\n<meta property=\"og:description\" content=\"Antecedentes El \u201cExpert Panel on effective ways of investing in Health\u201d se constituy\u00f3 con el objetivo de proporcionar asesoramiento no vinculante a la Comisi\u00f3n sobre cuestiones relacionadas con la eficacia, el acceso y la resiliencia de los sistemas de salud. El dictamen que comentamos, titulado \u201cInnovative payment models for high-cost innovative medicines\u201d, es interesante ya... M\u00e9s informaci\u00f3\" \/>\n<meta property=\"og:url\" content=\"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/\" \/>\n<meta property=\"og:site_name\" content=\"Faus Moliner\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-12T10:44:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-03-12T11:15:33+00:00\" \/>\n<meta name=\"author\" content=\"Merc\u00e8 Maresma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Merc\u00e8 Maresma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuts\" \/>\n\t<meta name=\"twitter:label3\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data3\" content=\"Merc\u00e8 Maresma\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/\"},\"author\":{\"name\":\"Merc\u00e8 Maresma\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/9b06a3741847fda133da58121f664fc2\"},\"headline\":\"La Comisi\u00f3n Europea publica la opini\u00f3n de sus expertos sobre modelos de financiaci\u00f3n de medicamentos innovadores\",\"datePublished\":\"2018-03-12T10:44:36+00:00\",\"dateModified\":\"2018-03-12T11:15:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/\"},\"wordCount\":449,\"publisher\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#organization\"},\"articleSection\":[\"Capsulas\",\"Dret Farmac\u00e8utic i \u201cLife Sciences\u201d\",\"Preu i Finan\u00e7ament P\u00f9blic\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/\",\"url\":\"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/\",\"name\":\"La Comisi\u00f3n Europea publica la opini\u00f3n de sus expertos sobre modelos de financiaci\u00f3n de medicamentos innovadores - Faus Moliner\",\"isPartOf\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#website\"},\"datePublished\":\"2018-03-12T10:44:36+00:00\",\"dateModified\":\"2018-03-12T11:15:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/faus-moliner.com\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La Comisi\u00f3n Europea publica la opini\u00f3n de sus expertos sobre modelos de financiaci\u00f3n de medicamentos innovadores\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#website\",\"url\":\"https:\/\/faus-moliner.com\/en\/\",\"name\":\"faus-moliner.com\",\"description\":\"Otro sitio realizado con WordPress\",\"publisher\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/faus-moliner.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#organization\",\"name\":\"Faus Moliner\",\"url\":\"https:\/\/faus-moliner.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg\",\"contentUrl\":\"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg\",\"width\":400,\"height\":283,\"caption\":\"Faus Moliner\"},\"image\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/2372042\/admin\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/9b06a3741847fda133da58121f664fc2\",\"name\":\"Merc\u00e8 Maresma\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/image\/602b9f178f2f88f72961f4d54be9dbf0\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ce15166c954e3d4a56c3b4d253d69d547f3aafe0ddae4b65e68f50a68ce7329c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ce15166c954e3d4a56c3b4d253d69d547f3aafe0ddae4b65e68f50a68ce7329c?s=96&d=mm&r=g\",\"caption\":\"Merc\u00e8 Maresma\"},\"url\":\"https:\/\/faus-moliner.com\/ca\/author\/merce-maresma\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La Comisi\u00f3n Europea publica la opini\u00f3n de sus expertos sobre modelos de financiaci\u00f3n de medicamentos innovadores - Faus Moliner","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/","og_locale":"ca_ES","og_type":"article","og_title":"La Comisi\u00f3n Europea publica la opini\u00f3n de sus expertos sobre modelos de financiaci\u00f3n de medicamentos innovadores - Faus Moliner","og_description":"Antecedentes El \u201cExpert Panel on effective ways of investing in Health\u201d se constituy\u00f3 con el objetivo de proporcionar asesoramiento no vinculante a la Comisi\u00f3n sobre cuestiones relacionadas con la eficacia, el acceso y la resiliencia de los sistemas de salud. El dictamen que comentamos, titulado \u201cInnovative payment models for high-cost innovative medicines\u201d, es interesante ya... M\u00e9s informaci\u00f3","og_url":"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/","og_site_name":"Faus Moliner","article_published_time":"2018-03-12T10:44:36+00:00","article_modified_time":"2018-03-12T11:15:33+00:00","author":"Merc\u00e8 Maresma","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"Merc\u00e8 Maresma","Temps estimat de lectura":"2 minuts","Written by":"Merc\u00e8 Maresma"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/#article","isPartOf":{"@id":"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/"},"author":{"name":"Merc\u00e8 Maresma","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/9b06a3741847fda133da58121f664fc2"},"headline":"La Comisi\u00f3n Europea publica la opini\u00f3n de sus expertos sobre modelos de financiaci\u00f3n de medicamentos innovadores","datePublished":"2018-03-12T10:44:36+00:00","dateModified":"2018-03-12T11:15:33+00:00","mainEntityOfPage":{"@id":"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/"},"wordCount":449,"publisher":{"@id":"https:\/\/faus-moliner.com\/en\/#organization"},"articleSection":["Capsulas","Dret Farmac\u00e8utic i \u201cLife Sciences\u201d","Preu i Finan\u00e7ament P\u00f9blic"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/","url":"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/","name":"La Comisi\u00f3n Europea publica la opini\u00f3n de sus expertos sobre modelos de financiaci\u00f3n de medicamentos innovadores - Faus Moliner","isPartOf":{"@id":"https:\/\/faus-moliner.com\/en\/#website"},"datePublished":"2018-03-12T10:44:36+00:00","dateModified":"2018-03-12T11:15:33+00:00","breadcrumb":{"@id":"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/faus-moliner.com\/ca\/la-comision-europea-publica-la-opinion-expertos-modelos-financiacion-medicamentos-innovadores\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/faus-moliner.com\/ca\/"},{"@type":"ListItem","position":2,"name":"La Comisi\u00f3n Europea publica la opini\u00f3n de sus expertos sobre modelos de financiaci\u00f3n de medicamentos innovadores"}]},{"@type":"WebSite","@id":"https:\/\/faus-moliner.com\/en\/#website","url":"https:\/\/faus-moliner.com\/en\/","name":"faus-moliner.com","description":"Otro sitio realizado con WordPress","publisher":{"@id":"https:\/\/faus-moliner.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/faus-moliner.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/faus-moliner.com\/en\/#organization","name":"Faus Moliner","url":"https:\/\/faus-moliner.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg","contentUrl":"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg","width":400,"height":283,"caption":"Faus Moliner"},"image":{"@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/2372042\/admin\/"]},{"@type":"Person","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/9b06a3741847fda133da58121f664fc2","name":"Merc\u00e8 Maresma","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/image\/602b9f178f2f88f72961f4d54be9dbf0","url":"https:\/\/secure.gravatar.com\/avatar\/ce15166c954e3d4a56c3b4d253d69d547f3aafe0ddae4b65e68f50a68ce7329c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ce15166c954e3d4a56c3b4d253d69d547f3aafe0ddae4b65e68f50a68ce7329c?s=96&d=mm&r=g","caption":"Merc\u00e8 Maresma"},"url":"https:\/\/faus-moliner.com\/ca\/author\/merce-maresma\/"}]}},"_links":{"self":[{"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/posts\/17457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/comments?post=17457"}],"version-history":[{"count":0,"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/posts\/17457\/revisions"}],"wp:attachment":[{"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/media?parent=17457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/categories?post=17457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/tags?post=17457"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/coauthors?post=17457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}